|LETTER TO THE EDITOR
|Year : 2018 | Volume
| Issue : 2 | Page : 72
Clinical utility of hyperbaric oxygen therapy in dentistry
Thorakkal Shamim BDS, MDS
Department of Dentistry, Government Taluk Head Quarters Hospital, Malappuram, Kerala, India
|Date of Web Publication||3-Jul-2018|
Department of Dentistry, Government Taluk Head Quarters Hospital, Malappuram, Kerala
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Shamim T. Clinical utility of hyperbaric oxygen therapy in dentistry. Med Gas Res 2018;8:72
I read with great interest the article Clinical utility of hyperbaric oxygen therapy in genitourinary medicine by Gandhi et al. in Medical Gas Research. I would like to suggest clinical utility of hyperbaric oxygen therapy in dentistry with emphasis on recent studies done on necrotizing fasciitis, wound dehiscence after intraoral bone grafting in the nonirradiated patients,osteoradionecrosis of mandible and oral submucous fibrosis.
It was evident from a case series study conducted at Australia that hyperbaric oxygen therapy have an additional role in the management of necrotizing fasciitis as a complication of odontogenic infection in medically complex patients. It was evident from a case series study conducted at Denmark that hyperbaric oxygen may only be optional in head and neck necrotizing fasciitis.
Hyperbaric oxygen therapy can be an effective adjunctive therapy in the treatment of nonirradiated patients with wound dehiscence due to chronic maxillary sinus problems or traumatic episode after intraoral bone grafting. Hyperbaric oxygen therapy can be recommended for stage I and II osteoradionecrosis and for selected cases of stage III osteoradionecrosis (staging of osteonecrosis based on the classification of Notani et al.).
The Division of Head and Neck Oncology of Dana-Farber/Brigham and Women’s Cancer Center, USA does not recommend the routine use of hyberbaric oxygen therapy for the prevention or management of osteoradionecrosis and they recommend adjunctive hyberbaric oxygen therapy in exceptionally high risk cases where there is failed history of conservative therapy and subsequent surgical resection.
Hyperbaric oxygen therapy as a therapeutic remedy in oral submucous fibrosis is underscored by increasing oxygen tension in oxygen-deficient tissue superadded with potent anti-inflammatory action.,
| References|| |
Gandhi J, Seyam O, Smith NL, Joshi G, Vatsia S, Khan SA. Clinical utility of hyperbaric oxygen therapy in genitourinary medicine. Med Gas Res
Bayetto K, Cheng A, Sambrook P. Necrotizing fasciitis as a complication of odontogenic infection: a review of management and case series. Aust Dent J
Fauno Thrane J, Pikelis A, Ovesen T. Hyperbaric oxygen may only be optional in head and neck necrotizing fasciitis: a retrospective analysis of 43 cases and review of the literature. Infect Dis (Lond)
Hollander MHJ, Boonstra O, Timmenga NM, Schortinghuis J. Hyperbaric oxygen therapy for wound dehiscence after intraoral bone grafting in the nonirradiated patient: A Case Series. J Oral Maxillofac Surg
Dieleman FJ, Phan TTT, van den Hoogen FJA, Kaanders J, Merkx MAW. The efficacy of hyperbaric oxygen therapy related to the clinical stage of osteoradionecrosis of the mandible. Int J Oral Maxillofac Surg
Sultan A, Hanna GJ, Margalit DN, et al. The use of hyperbaric oxygen for the prevention and management of osteoradionecrosis of the jaw: a Dana-Farber/Brigham and Women’s Cancer Center multidisciplinary guideline. Oncologist
Kumar MA, Radhika B, Gollamudi N, Reddy SP, Yaga US. Hyperbaric oxygen therapy-a novel treatment modality in oral submucous fibrosis: a review. J Clin Diagn Res
Sharma M, Radhakrishnan R. Limited mouth opening in oral submucous fibrosis: reasons, ramifications, and remedies. J Oral Pathol Med
Copyright license agreement: The Copyright License Agreement has been signed by all authors before publication.
Plagiarism check: Checked twice by iThenticate.
Peer review: Externally peer reviewed.
Open peer reviewer: Nemoto Edwin, University of New Mexico Health
Sciences Center, USA.